IONS - Ionis Pharmaceuticals - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

IONS is currently covered by 17 analysts with an average price target of $58.55. This is a potential upside of $15.1 (34.75%) from yesterday's end of day stock price of $43.45.

Ionis Pharmaceuticals's activity chart (see below) currently has 210 price targets and 209 ratings on display. The stock rating distribution of IONS is 71.43% BUY, 25% HOLD and 3.57% SELL.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 47.05% with an average time for these price targets to be met of 176.54 days.

Highest price target for IONS is $77, Lowest price target is $45, average price target is $60.29.

Most recent stock forecast was given by MICHAEL ULZ from MORGAN STANLEY on 31-Jul-2025. First documented stock forecast 12-Aug-2014.

Currently out of the existing stock ratings of IONS, 40 are a BUY (71.43%), 14 are a HOLD (25%), 2 are a SELL (3.57%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Hold

$62

$19.02 (44.25%)

$55

4 days ago
(31-Jul-2025)

4/6 (66.67%)

$19.02 (44.25%)

41

Hold

$57

$14.02 (32.62%)

$85

1 months 3 days ago
(01-Jul-2025)

0/6 (0%)

$17.06 (42.71%)

Hold

$57

$14.02 (32.62%)

$51

1 months 3 days ago
(01-Jul-2025)

6/8 (75%)

$17.06 (42.71%)

24

Hold

$48

$5.02 (11.68%)

$45

1 months 23 days ago
(12-Jun-2025)

2/7 (28.57%)

$12.38 (34.76%)

79

Buy

$64

$21.02 (48.91%)

3 months 3 days ago
(01-May-2025)

2/6 (33.33%)

$32.29 (101.83%)

11

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is IONS (Ionis Pharmaceuticals) average time for price targets to be met?

On average it took 176.54 days on average for the stock forecasts to be realized with a an average price target met ratio 47.05

Which analyst has the current highest performing score on IONS (Ionis Pharmaceuticals) with a proven track record?

ESTHER RAJAVELU

Which analyst has the most public recommendations on IONS (Ionis Pharmaceuticals)?

Esther Rajavelu has 8 price targets and 3 ratings on IONS

Which analyst is the currently most bullish on IONS (Ionis Pharmaceuticals)?

Yale Jen with highest potential upside - $55.02

Which analyst is the currently most reserved on IONS (Ionis Pharmaceuticals)?

Salveen Richter with lowest potential downside - -$5.98

Ionis Pharmaceuticals in the News

Ionis Pharmaceuticals Second Quarter 2025 Earnings: Beats Expectations

Ionis Pharmaceuticals (NASDAQ:IONS) Second Quarter 2025 Results Key Financial Results Revenue: US$452.0m (up 101% from 2Q 2024). Net income: US$124.0m (up from US$66.3m loss in 2Q 2024). Profit margin: 27% (up from net loss in 2Q 2024). The move to profitability was driven by higher revenue. EPS: US$0.78 (up from US$0.45 loss in 2Q 2024)....

Ionis Pharmaceuticals Inc (IONS) Q2 2025 Earnings Call Highlights: Revenue Surge and Strategic ...

Revenue: $452 million for Q2 2025, a two-fold increase year-over-year; $584 million for the first six months of 2025, nearly 70% increase versus prior year. Net Product Sales (Tryngolza): $19 million for Q2 2025, reflecting a threefold increase quarter-over-quarter. Royalty Revenues: Approximately $70 million in Q2 2025, a 10% increase. Non-GAAP Net Income: $154 million...
Show more

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?